Which pharmaceutical product's price increase of approximately 5,000% in 2015 led to congressional hearings and new discussions about medical product pricing ethics?

In the complex world of medical product pricing, companies must navigate regulatory requirements, market demands, and ethical considerations. One pharmaceutical company made headlines in 2016 with a controversial pricing strategy that sparked national debate about medication accessibility and corporate responsibility. This poll tests your knowledge about this significant case study that changed how many medical products are priced today and led to new industry guidelines.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Daraprim (pyrimethamine), used to treat toxoplasmosis, increased from $13.50 to $750 per tablet by Turing Pharmaceuticals
EpiPen, used for severe allergic reactions, increased from $50 to $600 for a two-pack by Mylan
Insulin products by Eli Lilly, which saw a 1,200% price increase between 1996 and 2015
Sovaldi (sofosbuvir), the hepatitis C treatment priced at $1,000 per pill by Gilead Sciences